E-therapeutics plc Shares Now Trading on JP Jenkins

e-therapeutics plc, a leader in computational biology for RNAi medicinals, has officially listed its shares on the JP Jenkins trading platform. This development provides a new venue for trading the shares associated with the company's stock symbol ETX. The consulting firm specializes in combining computational tools with biological data to pioneer RNAi medicines targeting severe diseases.

JP Jenkins is well-known for facilitating the trading of shares from unlisted companies, enhancing the accessibility for investors and existing shareholders to engage through a matched bargain system. This move to JP Jenkins from AIM offers ETX shareholders and potential investors more flexible trading opportunities during regular business hours through their stockbrokers.

The listing on JP Jenkins will feature indicative pricing and transaction history for e-therapeutics’ shares on the platform’s site, showcasing the company’s ongoing progress and operational transparency. The move intends to bolster liquidity and investment attraction, aligning with the company’s growth plans in addressing areas of unmet medical need like metabolic dysfunction-associated steatohepatitis and dry age-related macular degeneration.